使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to the Amneal Pharmaceuticals First Quarter 2024 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony Dimeo.
各位早安,歡迎參加 Amneal Pharmaceuticals 2024 年第一季財報電話會議。現在我將把電話交給 Amneal 投資人關係主管 Tony Dimeo。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Good morning, and thank you for joining Amneal Pharmaceuticals' First Quarter 2024 earnings call. Today, we issued a press release reporting Q1 results. The earnings press release and presentation are available at amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to, management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled cautionary statements and forward-looking statements for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliation to GAAP are in the earnings release and presentation.
各位早安,感謝您加入 Amneal Pharmaceuticals 2024 年第一季財報電話會議。今天我們發布新聞稿,公布第一季業績。財報新聞稿與簡報可於 amneal.com 取得。本次電話會議中所作之某些陳述,涉及非歷史事實之事項(包括但不限於管理層的展望或預測),屬於前瞻性陳述,且僅基於我們目前可取得之資訊。請參閱「警示性陳述與前瞻性陳述」章節,以了解可能影響未來表現之因素。我們亦將討論非 GAAP 衡量指標。關於這些衡量指標的使用及與 GAAP 的調節資訊,載於財報新聞稿與簡報中。
On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs; Tasos Konidaris, CFO; our commercial leaders, Andy Boyer for generics, Joe Renda for specialty; and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.
今天與會者包括共同創辦人暨共同執行長 Chirag 與 Chintu Patel;財務長 Tasos Konidaris;我們的商務領導團隊:學名藥業務的 Andy Boyer、專科藥業務的 Joe Renda;以及法務長 Jason Daly。現在我把電話交給 Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Tony. Good morning to everyone. Our first quarter performance was outstanding. Record Q1 revenues of $659 million grew 18%. For the first time, all three of our segments generated double digit growth in the same quarter.
謝謝你,Tony。各位早安。我們第一季的表現非常出色。第一季營收創新高,達 6.59 億美元,成長 18%。這是我們首次在同一季度三大事業部門皆實現雙位數成長。
Q1 adjusted EBITDA of $152 million grew by 31% as strong execution continues to drive sustainably higher levels of profits. As momentum builds across Amneal, we are confident in our ability to achieve our financial commitments for 2024 and beyond.
第一季調整後 EBITDA 為 1.52 億美元,成長 31%;強勁的執行力持續推動獲利水準穩健提升。隨著 Amneal 各項業務動能持續增強,我們對於達成 2024 年及未來的財務承諾充滿信心。
Our strategic vision for Amneal is to be a global, diversified pharmaceutical company that provides patients, providers and payers with access to high-quality, affordable and essential medicines.
我們對 Amneal 的策略願景,是成為一家全球化、多元化的製藥公司,為病患、醫療提供者與支付方提供高品質、可負擔且不可或缺的藥品之可近性。
In the U.S., AmnioFill is approximately $175 million prescriptions per year in retail pharmacies. We provide complex genetics medicines such as transdermals, topicals, oral solids and opthalmics. For hospitals and clinics, we supply important acute care injectables where there are chronic shortages. In biosimilars, we are expanding access to oncology therapies and adding more to our portfolio. In specialty, our innovative medicines advance the standard of care, such as in Parkinson's disease. In our healthcare distribution business, we provide military veterans with access to high-quality medicines.
在美國,AmnioFill 在零售藥局每年約有 1.75 億張處方。我們提供複雜的學名藥產品,例如經皮貼片、外用製劑、口服固體劑型與眼科用藥。針對醫院與診所,我們供應在長期短缺情況下仍至關重要的急性照護注射劑。在生物相似藥方面,我們正擴大腫瘤治療的可近性,並持續將更多產品納入產品組合。在專科藥領域,我們的創新藥物推進照護標準,例如帕金森氏症治療。在醫療保健配送業務方面,我們為退伍軍人提供取得高品質藥品的管道。
Globally, we are addressing unmet healthcare needs in developing and developed countries. As we continue to grow larger, Amneal is leading new era of affordable medicines and having a significant societal impact. Nowhere in our commitment to this mission more evident than our recent approval of Naloxone.
在全球範圍內,我們正因應開發中國家與已開發國家的未被滿足之醫療需求。隨著我們持續擴大規模,Amneal 正引領可負擔藥品的新時代,並帶來顯著的社會影響。我們對此使命的承諾,最明顯的例證之一就是近期 Naloxone 的核准。
Opioid overdose remains a US public health care emergency. We are expanding access to this critical rescue medicine as an OTC product at pharmacies, and for the public interest, through states and cities across the United States. We were pleased to finalize our partnership with the State of California with more to come. We are so proud that this essential life-saving medicine is made in America and manufacturing here in New Jersey by Amneal.
阿片類藥物過量仍是美國公共衛生緊急事件。我們正以非處方(OTC)產品形式在藥局擴大此關鍵救命藥物的可近性,並基於公共利益,透過全美各州與城市推廣。我們很高興已與加州州政府完成合作夥伴關係的定案,後續還會有更多進展。我們深感自豪,這款不可或缺的救命藥物在美國製造,並由 Amneal 於新澤西州進行生產。
Let me now walk through our business at a high-level where we remain confident in our strategy, our ability to execute well and drive growth and the opportunity to have a tremendous impact.
接下來我將從高層次概述我們的業務;我們對策略、卓越執行與成長動能,以及創造巨大影響的機會,仍充滿信心。
First, our affordable medicines business, which is our genetics segment has consistently grown each year since 2019. We are seeing this growth accelerate in 2024, driven by our diverse portfolio of retail, injectables and biosimilars. Amneal has a track record of quality, innovation and customer service.
首先是我們的可負擔藥品業務,也就是學名藥事業部,自 2019 年以來每年都持續成長。在 2024 年,我們看到成長正在加速,主要由多元的零售產品組合、注射劑與生物相似藥所帶動。Amneal 在品質、創新與客戶服務方面具備良好紀錄。
Those hallmarks continue to resonate in the U.S. pharmaceutical market, plagued by supply shortages with perpetual demand for high-quality medicines. The durability of our complex portfolio and regular cadence of new launches each year position Amneal well to continue expanding our leadership position in affordable medicines and driving sustainable long-term growth.
在供應短缺困擾、且對高品質藥品需求長期存在的美國製藥市場中,這些核心優勢持續獲得共鳴。我們複雜產品組合的韌性,以及每年規律推出新產品的節奏,使 Amneal 具備良好定位,可持續擴大在可負擔藥品領域的領導地位並推動可持續的長期成長。
In the retail pharmaceutical market, our portfolio of around 240 medicines is complex and diversified. With industry-wide supply chain disruption due to site inspections and manufacturer discontinuations, price erosion in the United States generic industry remains lower than it has been in several years.
在零售藥品市場,我們約 240 項藥品的產品組合兼具複雜性與多元化。由於場址稽查與製造商停產造成全產業供應鏈中斷,美國學名藥產業的價格侵蝕幅度仍低於過去數年水準。
In injectables, we are expanding our portfolio and have a significant capacity to help address drug shortages in hospitals and clinics. Our injectable strategy focuses on providing unique ready-to-use products like our recent launch of PEMRYDI RTU for the treatment of certain lung cancers Across retail and injectables, we are on track to launch over 30 new products this year following our record 39 new launches last year.
在注射劑方面,我們正擴充產品組合,並具備可觀產能,協助因應醫院與診所的藥品短缺。我們的注射劑策略聚焦於提供獨特的即用型(RTU)產品,例如近期推出的 PEMRYDI RTU,用於治療特定肺癌。橫跨零售與注射劑業務,我們今年可望推出超過 30 項新產品,延續去年創紀錄的 39 項新產品上市。
In biosimilars, we are seeing the next wave of affordable medicines. From 2024 to 2028, an estimated $192 billion in annual branded biologics value will lose exclusivity. We expect most biosimilar markets to be less competitive, given the inherent complex IT complexities of these molecules and the investment required to bring them to market.
在生物相似藥方面,我們正迎來下一波可負擔藥品浪潮。從 2024 年到 2028 年,估計每年將有 1,920 億美元的品牌生物製劑價值失去獨占權。我們預期多數生物相似藥市場的競爭將較不激烈,原因在於這些分子本身具有固有的複雜性,以及將其推向市場所需的投資。
Adoption rates for early biosimilars are now 80%, particularly in oncology where we operate. Our excellent commercial team is driving strong adoption at both community oncology and hospital-integrated delivery networks. That, coupled with our pipeline and with trusted partners, gives us confidence in continued momentum. We are well on our way to achieving over $125 million of revenue in 2024 with $90 million in biosimilars revenue over the last 12 months. We look to in-license one to two biosimilars each year or more and to be vertically integrated over time.
早期生物相似藥的採用率目前已達 80%,尤其是在我們所布局的腫瘤領域。我們優秀的商務團隊正推動社區腫瘤診所與醫院整合式照護網路的強勁採用。再加上我們的產品管線與值得信賴的合作夥伴,使我們對動能延續充滿信心。我們正穩步邁向 2024 年營收超過 1.25 億美元的目標,且過去 12 個月生物相似藥營收已達 9,000 萬美元。我們計畫每年引進授權(in-license)一到兩項或更多生物相似藥,並隨時間推進垂直整合。
Internationally, we continue to expand our reach and build a strong foundation. This is happening most notably in India, where we are building a customized portfolio of therapies for unmet needs like critical care, ophthalmology, oncology and diagnostics. In other geographies, we are working with partners to register and commercialize select and new products. We expect international expansion will add $50 million to $100 million in revenues by 2027 and rapidly scale up to that.
在國際市場方面,我們持續擴大觸及範圍並建立堅實基礎。其中最顯著的是在印度,我們正打造一套客製化治療產品組合,以滿足重症照護、眼科、腫瘤與診斷等未被滿足的需求。在其他地區,我們正與合作夥伴合作,進行特定與新產品的註冊與商業化。我們預期到 2027 年,國際擴張將帶來 5,000 萬至 1 億美元的營收增量,並將快速擴大至該水準。
Next, in our specialty business, we continued to make good progress with our key neurology and endocrinology branded products as revenues are growing double digits. In Q1, we successfully launched ONGENTYS - an adjunctive therapy for Parkinson's disease, which we recently in-licensed to our specialty portfolio.
接著,在我們的專科藥業務方面,隨著營收呈雙位數成長,我們的核心神經科與內分泌科品牌產品持續取得良好進展。第一季,我們成功推出 ONGENTYS——一項用於帕金森氏症的輔助治療藥物,該產品近期已透過授權引進至我們的專科藥產品組合。
Next up is IPX203 with our action date is on August 7th. Carbidopa Levodopa has been the main therapy for Parkinson's disease for over five decades. We believe IPX203 meaningfully advances that standard of care with a broad application for all patients.
接下來是 IPX203,我們的行動日期為 8 月 7 日。Carbidopa/Levodopa 在過去五十多年一直是帕金森氏症的主要治療方式。我們相信 IPX203 能夠實質推進該照護標準,並可廣泛適用於所有病患。
In our AvKARE distribution business, we have more than doubled revenues and profits since our acquisition in 2020. We are expanding all three channels: distribution, government and unit dose. Driven by new products from suppliers, including Amneal, we now expect over $650 million in AvKARE revenue next year as we expect this to remain a high-growth business. In short, we're starting 2024 with very strong momentum, our diversified growth profile is sustainable, and our financial performance is accelerating remarkably. I'll now hand it to Chintu.
在我們的 AvKARE 配銷業務中,自 2020 年收購以來,我們的營收與獲利已成長逾一倍。我們正在擴展三大通路:配銷、政府與單位劑量(unit dose)。在供應商(包括 Amneal)推出新產品的帶動下,我們目前預期 AvKARE 明年營收將超過 6.5 億美元,因為我們預期這仍將是一項高成長業務。總而言之,我們以非常強勁的動能展開 2024 年,我們多元化的成長輪廓具可持續性,而我們的財務表現正顯著加速。接下來我把時間交給 Chintu。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Good morning, everyone. Thank you to -- thank you, Chirag, and thank you to the global Amneal family who work hard every day to help make healthy possible. I will discuss how our core strengths in both operations and innovation provides us with a long runway for sustainable top- and bottom-line growth.
各位早安。謝謝——謝謝你,Chirag,也謝謝每天努力工作、協助讓健康成為可能的全球 Amneal 大家庭。我將說明我們在營運與創新兩方面的核心優勢,如何為我們帶來可持續的營收與獲利長期成長跑道。
First, quality has been at the center of everything we do since our founding in 2002. We continue to invest in quality through automation and AI technologies to advance our global infrastructure. Our success is also driven by our commitment to operational excellence, ongoing efficiency programs and a robust supply chain.
首先,自 2002 年創立以來,品質一直是我們一切工作的核心。我們持續透過自動化與 AI 技術投資品質,以推進我們的全球基礎設施。我們的成功也來自於對卓越營運的承諾、持續的效率提升計畫,以及強健的供應鏈。
All of our plants are FDA-approved. In each plant, we are driving optimization and efficiency programs to maintain our exceptional customer service levels and gain cost efficiencies. Across our supply chain, we are focused on what we call the 3Rs: redundancy, resiliency and reliability.
我們所有工廠皆通過 FDA 核准。在每一座工廠,我們推動最佳化與效率提升計畫,以維持卓越的客戶服務水準並取得成本效率。在整體供應鏈方面,我們聚焦於我們所稱的 3R:冗餘(redundancy)、韌性(resiliency)與可靠性(reliability)。
In particular, drug shortages are an ongoing challenge in the market. The US FDA lists 114 drug shortages, including 75 injectables, and Amneal will look to be part of the solution. We have about 20 commercial and pipeline injectables that are on the shortage list, including oncology medicines. We have also tripled our injectables manufacturing capacity in recent years at multiple plants. We continue to prioritize efforts to help alleviate shortages in the market, particularly for injectables.
特別是,藥品短缺仍是市場上的持續挑戰。美國 FDA 列出 114 項藥品短缺,其中包含 75 項注射劑,而 Amneal 將致力成為解決方案的一部分。我們約有 20 項已商業化與研發中的注射劑位列短缺清單,其中包含腫瘤用藥。近年來,我們也在多座工廠將注射劑製造產能提升至原來的三倍。我們將持續優先投入,協助緩解市場短缺問題,尤其是注射劑。
Second, our track record in innovation is very strong, and we are off to a great start in 2024 with five key complex product launches: Naloxone nasal spray, PEMRYDI RTU, Carvedilol ER, FML eye drops, and generic Ciprodex. We currently have 86 new products, ANDA's pending, of which 63 are non -oral solids. In addition, we have 67 pipeline products, 94% of which are non-oral solid.
第二,我們在創新方面的實績非常強勁,且 2024 年開局良好,已推出五項關鍵的複雜產品:那洛酮(Naloxone)鼻噴劑、PEMRYDI RTU、Carvedilol ER、FML 眼藥水,以及 Ciprodex 的學名藥。目前我們有 86 項新產品的 ANDA 申請待審,其中 63 項為非口服固體劑型。此外,我們有 67 項研發管線產品,其中 94% 為非口服固體劑型。
With our ongoing shift towards complex innovations, we have improved our R&D efficiencies and are spending less internally, which allows us to allocate more investment towards external R&D over time. We were so proud of last week's approval of Naloxone nasal spray, a life-saving treatment for drug overdoses. This is a tremendous milestone for the entire team at Amneal. The product is now available through retail pharmacies as an OTC product, and through states and counties across the U.S., we have built robust manufacturing capacity to make up to 10 million to pack starting next year.
隨著我們持續轉向複雜創新,我們提升了研發效率並降低內部支出,使我們得以隨時間將更多投資配置到外部研發。我們對上週那洛酮鼻噴劑獲准感到非常自豪,這是一種可挽救生命、用於藥物過量的治療。這對 Amneal 全體團隊而言是重大的里程碑。該產品目前已作為 OTC 產品透過零售藥局供應;同時也透過美國各州與郡縣提供。我們已建立強健的製造產能,從明年起可生產最多 1,000 萬包裝。
We are significantly expanding access to help address the opioid crisis that impacts so many Americans. In injectables, we expect to launch over 10 new products this year following the 14 new injectables we launched in 2023. Our R&D focus is on oncology, ready-to-use bags and long acting injectables. For the years, we have been meeting with clinicians to understand their needs. This emphasis on the voice of the customer has allowed us to develop unique presentations of existing products.
我們正大幅擴大可近性,以協助因應影響眾多美國人的類鴉片危機。在注射劑方面,繼 2023 年推出 14 項新注射劑後,我們預期今年將再推出超過 10 項新產品。我們的研發重點聚焦於腫瘤、即用型輸液袋(ready-to-use bags)與長效注射劑。多年來,我們持續與臨床醫師會面以了解其需求。這種重視客戶聲音的作法,使我們得以為既有產品開發出獨特的劑型/呈現方式。
Last month, we launched our first 505(b)(2) injectable in PEMRYDI RTU. These new ready-to-use presentation of a frequently used oncology magazine can improve efficiency and reduce medication errors. We look to launch 2 to 3 505(b)(2) injectables each year, with approximately 15 in development.
上個月,我們推出首個 505(b)(2) 注射劑 PEMRYDI RTU。這種常用腫瘤藥物的新即用型呈現方式,可提升效率並降低用藥錯誤。我們目標是每年推出 2 到 3 項 505(b)(2) 注射劑,目前約有 15 項在開發中。
Next, biosimilars continue to be a key area of strategic focus. Building on the success of our first three commercial products, we in-licensed 2 denosumab biosimilar candidate for Prolia and XGEVA in Q4. Those programs continue to progress with our development partner, mAbxience. In addition, we are pleased to share that in Q1, we in-licensed two additional peg-filgrastim pipeline programs: on-body injector and prefilled auto-injector.
接著,生物相似藥仍是重要的策略聚焦領域。在我們前三項商業化產品成功的基礎上,我們於第四季引進授權(in-license)2 項 denosumab 生物相似藥候選產品,用於 Prolia 與 XGEVA。這些計畫正與我們的開發夥伴 mAbxience 持續推進。此外,我們也很高興分享,在第一季我們另引進授權兩項 peg-filgrastim 研發管線計畫:貼附式注射器(on-body injector)與預充式自動注射器(prefilled auto-injector)。
Today, approximately 30% to 40% of the backfill existing market is on-body and fewer competitors are expected in this space. In total, we have three commercial biosimilars and four more under development, all in oncology. As we establish Amneal as a key biosimilar player, we look to add more opportunistic biosimilar molecules to our pipeline over time. Internationally, we have distribution partners in place for approximately 40 emerging markets -- market countries, including strong markets like Saudi Arabia, Mexico, South Africa and the Philippines. We are registering products globally, including in Europe, Canada, China and emerging markets.
目前,約 30% 到 40% 的既有市場回補(backfill)為貼附式(on-body),且預期在此領域的競爭者較少。整體而言,我們已有三項商業化生物相似藥,另有四項在開發中,皆聚焦於腫瘤領域。隨著我們將 Amneal 建立為重要的生物相似藥參與者,我們也將隨時間在管線中加入更多具機會性的生物相似藥分子。在國際市場方面,我們已在約 40 個新興市場國家建立配銷合作夥伴,包括沙烏地阿拉伯、墨西哥、南非與菲律賓等強勁市場。我們正於全球進行產品註冊,包括歐洲、加拿大、中國及新興市場。
In specialty, we are continuously evolving our R&D efforts to move up the value chain.
在專科領域,我們持續演進研發投入,以往價值鏈上游移動。
First, our IPX203 complete response submission is under review. Also, we are advancing our DHE auto-injector program for migraine and cluster headache. We transfer production internally and excited to complete our application later this year, which puts us in a good position to launch in the first half of next year once approved.
首先,我們的 IPX203 完整回覆(complete response)提交案正在審查中。此外,我們正推進用於偏頭痛與叢集性頭痛的 DHE 自動注射器計畫。我們正將生產轉回內部,並期待於今年稍晚完成申請;一旦獲准,這將使我們具備在明年上半年上市的良好條件。
In addition, we continue to advance our pipeline with K-114 for endocrinology and other programs. We look to launch one to two specialty products each year going forward.
此外,我們也持續推進包含用於內分泌的 K-114 及其他計畫在內的研發管線。展望未來,我們目標是每年推出一到兩項專科產品。
Overall, Amneal is expanding and growing in the key areas of medicine, complex generics, injectables, biosimilars, international, distribution, and specialty branding. We are so deeply passionate about our company's mission and purpose. and the good work that remains ahead.
整體而言,Amneal 正在關鍵醫療領域擴張並成長,包括複雜學名藥、注射劑、生物相似藥、國際市場、配銷,以及專科品牌。我們對公司的使命與宗旨,以及未來仍待完成的重要工作,懷抱深切熱情。
I will now pass it over to Tassos.
接下來我把時間交給 Tassos。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Thank you Chintu, and good morning. At a high level, our diversified business is driving sustainable, higher levels of revenues and profits and continued deleveraging. Our first quarter results were excellent, with total net revenue of $659 million, up 18%.
謝謝你,Chintu,大家早安。從整體來看,我們多元化的業務正推動營收與獲利達到更高且可持續的水準,並持續去槓桿。我們第一季表現非常出色,總淨營收為 6.59 億美元,年增 18%。
Q1 generics net revenue of $391 million grew 14%, driven by our diverse portfolio of complex products. Biosimilars generated $27 million in revenue, driven by (inaudible). New products launched in 2023 and 2024 added $19 million to Q1 revenue growth. In addition, the remaining base portfolio continued to grow due to the relevancy of our products, strong market demand, less pricing pressure and Amneal's high-quality supply chain.
第一季學名藥淨營收為 3.91 億美元,成長 14%,主要由我們多元的複雜產品組合帶動。生物相似藥貢獻 2,700 萬美元營收,主要由(聽不清)帶動。2023 年與 2024 年推出的新產品為第一季營收成長增加 1,900 萬美元。此外,其餘基礎產品組合也持續成長,原因包括我們產品的市場相關性、強勁的市場需求、較少的價格壓力,以及 Amneal 高品質的供應鏈。
Q1 specialty net revenues of $105 million grew 15%, driven by double digit growth of our key branded products, plus the recent launch of ONGENTYS in March.
第一季專科藥品淨營收為1.05億美元,成長15%,主要受我們關鍵品牌產品的雙位數成長帶動,並加上3月近期推出的ONGENTYS。
Q1 AvKARE net revenues of $163 million grew 33%, reflecting continued strong growth across all three customer channels driven by new products. Our Q1 adjusted gross margins of 42% increased 250 basis points year over year, and were ahead of our expectations. Strong gross margins were driven by the favorable mix of revenues that reflected the complexity of our portfolio combined with higher fixed overhead absorption.
第一季AvKARE淨營收為1.63億美元,成長33%,反映在新產品帶動下,三大客戶通路皆持續強勁成長。我們第一季調整後毛利率為42%,年增250個基點,且優於我們的預期。強勁的毛利率主要來自有利的營收組合,反映我們產品組合的複雜度,並結合較高的固定間接費用吸收。
Q1 adjusted EBITDA of $152 million grew 31% reflecting robust revenue growth, higher gross margins, tight management of operating expenses and a favorable comparison to prior year. Our leverage growth profile in Q1 is the blueprint for sustainable, higher P&L results for the company going forward.
第一季調整後EBITDA為1.52億美元,成長31%,反映強勁的營收成長、更高的毛利率、對營運費用的嚴格管理,以及相較去年同期的有利比較基期。我們第一季的槓桿成長模式,是公司未來實現可持續、更高損益表(P&L)成果的藍圖。
Q1 adjusted EPS of $0.14 grew 17%, driven by higher adjusted EBITDA, partially offset by interest costs. As a reminder, we have made substantial progress over the last four years, driving accelerated top- and bottom-line growth, reducing leverage and resolve legacy matters. As a result, our annual adjusted EBITDA has increased from $339 million in 2019 to $594 million over the last 12 months ended Q1 2024. Also, net leverage has declined from 7.4 times in 2019 to 4.6 times.
第一季調整後每股盈餘(EPS)為0.14美元,成長17%,主要由較高的調整後EBITDA帶動,但部分被利息成本抵銷。提醒各位,我們在過去四年已取得重大進展,推動營收與獲利加速成長、降低槓桿並解決歷史遺留事項。因此,我們年度調整後EBITDA已從2019年的3.39億美元,提高至截至2024年第一季的過去12個月5.94億美元。此外,淨槓桿已從2019年的7.4倍降至4.6倍。
Now, as I mentioned earlier, settling legacy -- legal matters has been a priority of ours. Two years ago, we settled Opana ER litigation, and we just made a final payment in Q1. In addition, today we announced that we reached agreement in principle for a nationwide opioid settlement payable over 10 years that resolves substantially all opioids litigation.
現在,如我先前提到的,解決歷史遺留——法律事項一直是我們的優先要務。兩年前,我們已就Opana ER訴訟達成和解,而我們剛在第一季完成最後一筆付款。此外,我們今天宣布,已就一項為期10年支付的全國性阿片類藥物和解達成原則性協議,該協議可解決幾乎所有阿片類藥物訴訟。
Accordingly, in the first quarter, we recorded a pretax charge of $94 million, which reflects cash payments in the supply of logs and nasal spray, both over the next 10 years. As a result, we have now substantially resolved these two legacy legal matters, which removes this overhang from the company.
因此,在第一季我們認列了9,400萬美元的稅前費用,反映未來10年內就供應原木與鼻噴劑的現金支付。因此,我們現在已基本解決這兩項歷史遺留法律事項,消除了公司頭上的不確定因素。
Given the strong start of the year and our improved visibility, including the recent outlooks and approval for targeting the higher end of our full year outlook. As a reminder, we expect total net revenue of $2,550 million to $2,650 million and adjusted EBITDA of $580 million to $620 million, which reflects high single digit growth on both top and bottom line.
鑑於今年開局強勁且能見度提升(包括近期的展望與核准),我們正以達成全年展望區間的高端為目標。提醒各位,我們預期總淨營收為25.5億至26.5億美元,調整後EBITDA為5.8億至6.2億美元,反映營收與獲利皆為高個位數成長。
With that, let me turn the call over to Chirag.
接下來,我把電話交給Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Well, thank you, Tassos. Amneal's Q1 performance was excellent, across the board and reflects our continued upward trajectory in driving higher financial results over the years. We are so excited about the opportunities ahead.
好的,謝謝你,Tassos。Amneal第一季表現非常出色,各方面皆然,並反映我們多年來持續向上、推動更高財務成果的軌跡。我們對未來的機會感到非常振奮。
Let's now open the call for Q&A.
現在我們開放問答(Q&A)。
Operator
Operator
(Operator Instructions) Nathan Rich, Goldman Sachs.
(接線員指示)Nathan Rich,高盛。
Nathan Rich - Analyst
Nathan Rich - Analyst
Yes, hi, good morning. Congratulations on a strong quarter, and thanks for the questions. Maybe, I wanted to start with Naloxone and specifically the California contract. Can you talk about when that contract starts and how long it is, and any details you can share, maybe, on the type of volume commitment that the state made and have you gotten additional interest from other states sort of on the back of that? And any comments on the margin profile of the Naloxone maybe relative to the corporate average would be helpful.
是的,嗨,早安。恭喜本季表現強勁,也謝謝讓我提問。我想先從Naloxone開始,特別是加州合約。能否談談該合約何時開始、期限多長,以及你們可以分享的任何細節,例如州政府承諾的採購量類型?另外,在此之後,是否也收到其他州的額外興趣?以及,若能評論一下Naloxone的利潤率概況,相對於公司平均水準,將會很有幫助。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Nathan, good morning. So, California supplies starts now, and we will see the increased demand as they ramp up our label. And according to the state's press release, they could buy up to $3.2 million units per year. We don't expect them to buy that in the 1st year, but they'll ramp it up as they go, somewhere between, we expect, $2 million to 3 million units in the State of California.
Nathan,早安。所以,加州的供應現在就開始了,隨著他們逐步擴大我們的標籤(產品)使用,我們會看到需求增加。根據州政府的新聞稿,他們每年最多可採購320萬支。我們不預期他們第一年就會買到這個量,但會逐步拉升;我們預期在加州大約會在200萬到300萬支之間。
The remaining contractual terms are confidential. It was a great win for us, and we're very proud of the agreement with the State of California in trusting us to supply and valuing the 'Made in United States' product. So, we really appreciate it.
其餘合約條款屬機密。這對我們而言是一次很棒的勝利,我們也為與加州達成協議感到非常自豪,州政府信任我們供應,並重視「美國製造」的產品。因此,我們非常感謝。
In terms of the margin profile, it is going to be higher and accretive than the current gross margin.
就利潤率概況而言,它將高於目前的毛利率,並且具有增厚(accretive)效果。
(multiple speakers)
(多位講者)
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
It's obviously not just the (inaudible) issue, just the State of California, so this is impacting -- it's an issue across all of our states, and our commercial teams are actively engaged with other internal parties, both on the state and federal level. So really excited to kind of fill the incremental need that's going to provide for many years.
顯然,這不只是(聽不清)問題,也不只是加州一州的問題;這影響——這是我們所有州都面臨的議題。我們的商務團隊正積極與其他內部夥伴合作,無論在州或聯邦層級皆然。所以我們非常期待能滿足這項將持續多年、額外增加的需求。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yes. And we have built the capacity to supply 10 million units, up to 10 million units starting early next year. This year, we're producing somewhere between 2.5 million to 3 million units.
是的。而且我們已建立產能,從明年初開始可供應最高達1,000萬支。今年我們的產量大約在250萬到300萬支之間。
Nathan Rich - Analyst
Nathan Rich - Analyst
That's great. Maybe just a follow-up on the cadence of earnings this year. You know, Tasos, I know you kind of pointed to the high end of the range, but I think looking at the historical EBITDA cadence, I think 20% comes in the first quarter typically based on what you did this year, that would imply a number well above that kind of high end of the range. So, is there anything to kind of note on just earnings cadence this year that would be different than normal?
太好了。我想再追問一下今年獲利的節奏。你知道,Tasos,我知道你提到偏向區間高端,但從歷史EBITDA節奏來看,通常第一季約占全年20%;以你們今年第一季的表現來推算,似乎會暗示一個遠高於區間高端的數字。所以,今年在獲利節奏上是否有任何需要注意、會不同於以往的地方?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
It's, you know, you take one quarter, we can never annualize this, so if you think about we finished the year last year with EBITDA of, what, $554 million, right?
你知道,只看一個季度,我們永遠不能把它年化;所以如果你想想,我們去年年底的EBITDA是——多少來著——5.54億美元,對吧?
So, we added Q1 run rate, right? The last run rate of the four quarters now, it's almost $600 million - $594 million. So, the year is playing out how we were hoping it, which is acceleration of top- and bottom-line growth, right?
所以我們把第一季的運行率加進來,對吧?現在四個季度的最新運行率,接近6億美元——5.94億美元。所以,今年的進展正如我們所希望的那樣,也就是營收與獲利加速成長,對吧?
So, we have a so -- great, great improvement. So, now we are targeting the high end of the range, and we are saying is 'there more', right? And, you can count on us and tried to maximize the performance, but at the same time, right, we are also focused on driving and making investments primarily in our R&D, primarily in kind of tuck-in licensing deals in the biosimilar and complex drugs to not just maximize this year or the next, but build a long-term growth for 2026, 2027.
所以,我們有非常——很大、很大的改善。因此,我們現在以區間高端為目標,同時也在問「是否還有更多」,對吧?你可以相信我們會努力把表現最大化,但同時,對吧,我們也專注於推動並進行投資,主要在研發(R&D),以及在生物相似藥與複雜藥物方面的一些補強式(tuck-in)授權交易,不只是為了最大化今年或明年,而是為2026、2027建立長期成長。
So, you're not missing anything. The only thing I want to be mindful is I want to make sure we have room in our operating expenses to make investments over the next nine months, primarily in R&D and then also, depending how things play out with IPX203, kind of making sure we cannot make the right investments there to drive that growth as quickly as possible.
所以,你沒有漏掉任何事情。我唯一想留意的是,我想確保我們在未來九個月的營運費用中保留空間來進行投資,主要在研發;另外也要視IPX203的進展而定,確保我們能在那裡做出正確投資,以盡可能快速推動成長。
Nathan Rich - Analyst
Nathan Rich - Analyst
Okay. That's helpful. Thank you.
好的。這很有幫助。謝謝。
Operator
Operator
Les Sulewski, Truist Securities.
Les Sulewski,Truist Securities。
Les Sulewski - Analyst
Les Sulewski - Analyst
Good morning. Thank you for taking my questions. Can you just provide some initial update commentary on the ONGENTYS, given the new ownership structure, and perhaps some feedback from prescribers? And then, also on PEMRYDI, and I have a follow-up.
早安。謝謝你回答我的問題。在新的所有權架構之下,能否就 ONGENTYS 提供一些初步的最新進展評論,以及處方醫師端的一些回饋?另外也請談談 PEMRYDI,我還有一個追問。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yes, let me turn it over to Mr. Joe Renda here.
好的,讓我把問題交給 Joe Renda 先生。
Joe Renda - SVP & Chief Commercial Officer - Specialty
Joe Renda - SVP & Chief Commercial Officer - Specialty
Yes, thanks Les. So far, we've been very pleased with ONGENTYS, as well as the partnership with BIAL. It's been a great partnership, and we've been working very closely with them and their global team, executing upon the strategies that they've learned from over the years. I would say probably the three pieces of feedback that would be significant would be: one, we are hearing very positive feedback from prescribers; there was a concern that fit ONGENTYS would not be remaining in the market, so prescribers were very pleased when they heard we were going to be taking over this brand and we've been able to sign on a few more contracts from an access standpoint, so our goal there is to increase the access -- the market access that is for ONGENTYS and the market beyond what it was, and so far, we've been very pleased with that; performance and progress; and, finally, I would say one of the things we're looking at closely to kind of determine the uptick is what our NBRx performance has been new, new patients to brand, and were up some 20% in NBRxs from a performance standpoint.
好的,謝謝 Les。到目前為止,我們對 ONGENTYS 以及與 BIAL 的合作都非常滿意。這是一個很棒的合作夥伴關係,我們一直與他們及其全球團隊非常緊密地合作,執行他們多年來累積的策略。我想大概有三點重要回饋:第一,我們從處方醫師那裡聽到非常正面的回饋;先前曾有人擔心 ONGENTYS 可能不會繼續留在市場上,所以當處方醫師聽到我們將接手這個品牌時都非常高興;而且就可近性(access)的角度,我們也已經簽下了更多合約,因此我們的目標是提升 ONGENTYS 的市場可近性,並把市場覆蓋擴大到超過過去的水準;到目前為止,我們對這些表現與進展都很滿意。最後,我想我們也在密切觀察用以判斷成長動能的指標,也就是我們的 NBRx 表現——新病患導入品牌的處方數;從績效角度來看,NBRx 約成長了 20%。
So far, we're very pleased and it's been a great partnership, and it's also been a really good augmentation to Rytary.
到目前為止,我們非常滿意,這是一個很棒的合作夥伴關係,同時也確實對 Rytary 形成了很好的補強。
Unidentified Company Representative
Unidentified Company Representative
And Les, you had a question on PEMRYDI RTU. The way to think about that for annual rate is another complex innovation on the injectable side; it's our first 505(b)(2) launch. We'll do two to three years going forward, and it's a ready-to-use oncology therapy that reduces steps. So, think of it as a new vector of growth for the company.
Les,你也問到 PEMRYDI RTU。若以年化速度來看,它是注射劑端的另一項複雜創新;也是我們第一個 505(b)(2) 的上市產品。未來兩到三年我們會持續推進;它是一款可直接使用(ready-to-use)的腫瘤治療,能減少操作步驟。所以,可以把它視為公司新的成長向量。
Les Sulewski - Analyst
Les Sulewski - Analyst
Great. Appreciate that extra color. Now, moving on to IPX203 and your action date circled for August 7th - can you just talk about perhaps your launch readiness, your plans with the sales force and just overall impact potential guidance, if any? Thank you.
很好。感謝補充這些細節。接著談 IPX203,你們把 8 月 7 日的行動日期圈起來了——能否談談你們的上市準備情況、銷售團隊的規劃,以及整體潛在影響(若有的話)與任何指引?謝謝。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Yes. Go ahead
好的。請說。
Joe Renda - SVP & Chief Commercial Officer - Specialty
Joe Renda - SVP & Chief Commercial Officer - Specialty
Yes. So, first of all, I would say one of the things that is significant for us is we've really become a leader in the Parkinson's space, right? Rytary has enabled us to develop and deepen relationships with key prescribers and movement disorder specialists across the country, really in and around the world for that matter. And that also is coupled with the fact that we've developed a market access capability that has created an access stream for Rytary - that's the best in the in the Parkinson's community.
好的。首先,我想對我們而言很重要的一點是:我們確實已成為帕金森領域的領導者,對吧?Rytary 讓我們得以在全國各地、甚至可以說在全球,與關鍵處方醫師以及動作障礙專科醫師建立並深化關係。同時,我們也建立了市場准入(market access)能力,為 Rytary 打造了一條可近性通路——在帕金森社群中可說是最好的。
So, we enjoy some 70% commercial coverage in about 60 or so percent of the Part D coverage. And then the ONGENTYS that I just spoke to has enabled us to actually increase our prescriber base; we're going deeper now into general neurologists.
因此,我們在商業保險的覆蓋率約 70%,在 Part D 的覆蓋率約 60% 左右。另外,我剛才提到的 ONGENTYS 也讓我們實際上擴大了處方醫師基礎;我們現在更深入觸及一般神經科醫師。
So, when you look at our go-to-market strategy with IPX, the three components there are: one, leveraging and working off of those deep relationships that we've built over the last decade in the Parkinson's community. And then second is to leverage that market access capability that we have; we'll use that same strategy to gain access for IPX203, comparable to what we have with Rytary.
所以,當你看我們針對 IPX 的上市策略(go-to-market strategy),主要有三個組成:第一,運用並延續我們過去十年在帕金森社群中建立的深厚關係。第二,運用我們既有的市場准入能力;我們會用同樣的策略為 IPX203 取得可近性,目標是達到與 Rytary 類似的水準。
And then finally, I would say that the novel formulation that is IPX203 really offers greater efficacy, better on-time, fewer dosing. So, the Parkinson's community itself is very excited. In fact, just last night, we were at a Parkinson's Foundation Gala, and there's a lot of buzz and talk about when IPX203 is coming to market.
最後,我會說 IPX203 這個新穎配方確實能提供更高療效、更好的「on-time」時間,以及更少的給藥次數。因此帕金森社群本身非常興奮。事實上,就在昨晚我們參加帕金森基金會的晚宴,大家都在熱烈討論 IPX203 何時上市。
So we're very ready and eager to get the IPX203 to the hands of the patients that needed out there.
所以我們已經準備就緒,也非常期待能把 IPX203 交到真正需要的病患手上。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
And Les, in terms of potential peak revenues, assuming approval, we feel so great about it. Rytary right now, there's a couple of hundred million dollars in annual revenues, right? The guidance we have given about IPX203 is peak revenues of $300 million to $500 million. We think, based on the product profile and the fact that IPX203 is only being used by about 5% of the available patients, right -- right away, I'm sorry -- So, there is a tremendous market opportunity out there for the remaining 95% of the market that's not been utilizing Rytary, and I think a bit here revenues three to 500. I think it's just well within what the team is capable.
Les,至於潛在的峰值營收,在假設獲批的前提下,我們對此非常有信心。Rytary 目前的年營收是數億美元等級。我們先前給出的 IPX203 指引是:峰值營收 3 億到 5 億美元。我們認為,基於產品特性,以及目前(抱歉,我是說 Rytary)在可用病患中僅約 5% 有在使用——因此,對於其餘 95% 尚未使用 Rytary 的市場,存在非常巨大的市場機會;我認為 3 億到 5 億的營收目標完全在團隊能力範圍之內。我認為這確實是團隊完全做得到的。
Les Sulewski - Analyst
Les Sulewski - Analyst
Great. Appreciate it. Thank you.
很好。感謝分享。謝謝。
Operator
Operator
David Amsellem, Piper Sandler.
David Amsellem,Piper Sandler。
David Amsellem - Analyst
David Amsellem - Analyst
Thank you; just have a few questions. I wanted to drill down on the $100 million plus in new product revenue in 2024. Can you talk about the mix between retail and injectable contribution in that $100 million that's number one.
謝謝;我有幾個問題。我想深入了解你們在 2024 年新增產品營收超過 1 億美元的部分。第一,能否談談這 1 億美元中,零售端與注射劑端的貢獻組合?
Number two is, how much of the injectable contribution is coming from shortage products? Ours is a complex product. And so that's another question.
第二,注射劑端的貢獻中,有多少是來自短缺(shortage)產品?我們的產品屬於複雜產品。所以這也是另一個問題。
And then also, switching gears to our ALYMSYS or the bevacizumab, biosimilar - can you just talk about the dynamics here that are driving the strong sales? Is it limited competition in the market? Are there other things at play here? And just talk about your expectations for that product and what informs your $100 million plus in sales by 2025? Thank you.
另外,換個話題談 ALYMSYS 或 bevacizumab(貝伐珠單抗)生物相似藥——能否談談推動強勁銷售的市場動態?是因為市場競爭有限嗎?還是有其他因素在發揮作用?也請談談你們對該產品的預期,以及你們對 2025 年銷售超過 1 億美元的判斷依據是什麼?謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Great, David. Good morning. So, let me -- it's a new product launches - let's just go back a little bit last five years, if you go by the NPLs and you total that to this year's revenue is about $765 million we have added in new product launches.
很好,David。早安。那我先——談到新產品上市,我們先回顧一下過去五年:如果以 NPLs(新產品上市)來看,累計到今年的營收,我們透過新產品上市新增的營收約為 7.65 億美元。
And what we see going forward, and this is just within generics, injectables and biosimilars, we can break it down for you later on but stay on a bigger picture, is that why we are able to grow this, and why in the United States; this business, this is just US number. International is separate.
而我們往前看——這裡僅限於學名藥、注射劑與生物相似藥——我們之後可以再為你拆解更細,但先從大方向來說:我們之所以能夠成長、以及為何在美國(這裡的數字僅指美國業務;國際市場是另外分開的)。
Why this is a big deal? Because I think it's for over time because people have been focused on price erosion and have ignored the entire biggest market for the affordable medicines is United States, and we now expect the next 4 years, if you annualize our revenue of next four years from 28, that would be additional $800 million to $1 billion added to the new -- to NPLs. So, this is, you know, we've been working on such a strong pipeline and in-licensing strong products.
為什麼這很重要?因為我認為這是長期趨勢,大家一直把焦點放在價格侵蝕上,卻忽略了平價藥物最大的市場其實是美國;而我們現在預期,未來4年若將我們從28(起算)的未來四年營收年化,將會為新的——為NPLs額外增加8億至10億美元。所以,你知道的,我們一直在打造非常強勁的產品管線,並透過引進授權(in-licensing)取得強勢產品。
On page 7 of our presentation, we have listed out many of them - like 60 products being launched in 24 and 25, 15 of them are high value. So you can see it in more and more high values that happening as you go year out.
在我們簡報第7頁,我們列出了其中許多——例如在24年與25年將推出約60個產品,其中15個是高價值產品。所以你可以看到,隨著年度往後推進,發生的高價值產品會越來越多。
And, we have not disclosed certain pipeline assets for competitive reasons, as well as we have not disclosed some of the in-licensing products that we are have or working on it for competitive reasons. So, very excited to, and these are risk-adjusted number I gave you. So, this $100 million is -- the breakdown we can provide you later on between the --
另外,基於競爭因素,我們未揭露某些管線資產;同樣地,基於競爭因素,我們也未揭露一些我們已取得或正在洽談/推進的引進授權產品。所以,非常期待——而且我給你的這些數字都是風險調整後的。因此,這1億美元——我們之後可以再提供你在——之間的拆分明細。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Organic and providing. (multiple speakers)
有機成長以及提供。(多位發言者)
So, the $100 million, it's combination of a couple of things: combination of products, if you remember last year towards the at the end of Q4, quite a number of new products close to, I think ,13 or so products that were approved in Q4 of last year. So, that's kind of the annualization of those revenues, right? As well as new product launches this year.
所以,這1億美元是幾個因素的組合:產品的組合——如果你記得去年在第四季末,有相當多的新產品在去年第四季獲批,接近我想大約13個左右。所以,這基本上就是那些營收的年化,對吧?再加上今年的新產品上市。
So that $100 million number, it's not a certainty, but a high degree of confidence - point number one.
所以這1億美元的數字並非百分之百確定,但我們有很高的信心——第一點。
When you break it out between retail and injectable, it's pretty much almost split 50-50, 60-40 between. So, it's evenly split retail products like Naloxone, right, on one side, injectable products of like PEMRYDI, and there are many of the other smaller injectable products. So, it's pretty evenly split between retail and injectables.
當你把它拆分到零售與注射劑時,幾乎是接近對半分,大概50-50、或60-40左右。也就是說,一邊是像Naloxone這類的零售產品;另一邊是像PEMRYDI這類的注射劑產品,還有許多其他較小的注射劑產品。所以在零售與注射劑之間分布相當平均。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
And next, your next question on the shortages versus regular, where shortages make very small numbers at this point. It's our regular products that we've been expanding the market. So, demand is coming our way because we are the best quality and consistent supplier out in the market. So, our customers are trusting us, and more and more trust has been established.
接著,你問到缺貨(shortages)與一般(regular)的差異——目前缺貨帶來的數字非常小。主要是我們的一般產品在擴大市場。因此需求正在往我們這邊來,因為我們是市場上品質最好且供應最穩定的供應商。所以客戶信任我們,而且這種信任正在持續加深。
Your question regarding ALYMSYS, we have a very strong team. I mean that the commercial team has done a superb job; Amneal's reputation, Amneal's basket of 300 products - we bring a lot more to the table for our customers than if you are a pure play biosimilar.
你關於ALYMSYS的問題——我們有一支非常強的團隊。我的意思是,商業團隊做得非常出色;Amneal的聲譽、Amneal涵蓋300個產品的產品組合——相較於純做生物相似藥的公司,我們能為客戶提供更多價值。
So, this is why I believe that for the future you will see that companies being more successful, who have a broader portfolio and who are working closely, whether it's the oncologist, the community oncologist, all the hospitals, all the PBMs because we provide tremendous value to them. So, we have a better negotiating power with them or advantages versus the pure play biosimilars, and we're going to keep improving in those.
所以,我相信未來你會看到,那些擁有更廣泛產品組合、並且與各方密切合作的公司會更成功——不論是腫瘤科醫師、社區腫瘤科醫師、各家醫院、或所有PBM(藥品福利管理機構),因為我們能為他們提供巨大的價值。因此,我們在與他們談判時有更好的議價能力,或相較於純做生物相似藥的公司更具優勢,而我們也會持續在這些方面精進。
ALMSYS, you will see even higher market share coming up, as well as FYLNETRA when we add OBI, you will start seeing the uptake on the market share as well.
ALMSYS你會看到市占率還會再提高;另外,當我們為FYLNETRA加入OBI之後,你也會開始看到市占率的提升。
David Amsellem - Analyst
David Amsellem - Analyst
That's helpful. Just to clarify, the $100 million does not include Naloxone - I think I saw a footnote for that in the slides, but I just want to make sure that's correct. $100 million did not include Naloxone?
這很有幫助。我想再確認一下,這1億美元不包含Naloxone——我想我在投影片裡看到有註腳提到,但我想確認是否正確。這1億美元不包含Naloxone嗎?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
David, that's correct that the estimate we had on the Q4 call and reiterated $30 million plus for Naloxone, $100 million is for the rest of the NPLs this year.
David,沒錯。我們在第四季電話會議上估計並重申Naloxone為3,000萬美元以上;這1億美元是今年其餘NPLs的部分。
David Amsellem - Analyst
David Amsellem - Analyst
Great. Okay, helpful. Thank you.
很好。好的,很有幫助。謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
And you can see the file with my brother mentioned - five already launched, which are good value products complex.
而且你可以看到我兄弟提到的檔案——已經有五個上市,都是高價值、複雜的產品。
Operator
Operator
Balaji Prasad, Barclays.
Balaji Prasad,Barclays。
Balaji Prasad - Analyst
Balaji Prasad - Analyst
Hi, good morning, everyone, and congratulations on the results. A couple of questions from me. I was --starting on the generic side, I was slightly surprised to see Amneal's (inaudible) on Xifaxan. Bausch has been vehemently defending this from years, versus a host of generic companies, settled there, so how differentiated is (inaudible) versus others? How realistic of an opportunity is this versus any other generic company?
嗨,大家早安,恭喜本季業績。我有幾個問題。我先從學名藥(generic)這邊開始——我有點驚訝看到Amneal在Xifaxan上的(聽不清)。Bausch多年來一直非常強硬地捍衛這個產品,面對一大批學名藥公司;也有公司在那邊和解了,所以(聽不清)相較於其他公司有多大的差異化?相較於任何其他學名藥公司,這個機會到底有多現實?
And similar question on Restasis, too. For years, generic companies have flagged this as an opportunity and struggled to get approval for the (inaudible) and how should we think about it?
另外Restasis也有類似問題。多年來,學名藥公司一直把它視為機會,但在(聽不清)的核准上一直很吃力;我們應該如何看待這件事?
Secondly, on health care I saw that versus last quarter's presentation, where you have a long-term guidance, $600 million, you raised it to $650 million. What drove that increase in revenue guidance and what is the EBITDA impact of it? Thank you.
第二,關於醫療保健(health care),我看到相較於上一季簡報中你們給的長期指引6億美元,你們把它上調到6.5億美元。是什麼推動了營收指引的上調?對EBITDA的影響是什麼?謝謝。
(multiple speakers)
(多位發言者)
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Go ahead, Chintu.
Chintu,你先請。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Yes, hi, Balaji. Good morning and thank you. (inaudible) we always work on very unique and key products, and we do have a position based on something confidential - I don't want to get into the details.
好的,嗨,Balaji。早安,謝謝。(聽不清)我們一向聚焦在非常獨特且關鍵的產品上,而且我們基於一些機密事項確實有一個立場——我不想深入細節。
We are excited about the $5 billion opportunity, but it remains to be seen how it develops and multiple things that is involved. So, we cannot comment at this time and any of the details.
我們對這個50億美元的機會感到興奮,但它如何發展仍有待觀察,且牽涉多個因素。所以我們目前無法評論任何細節。
On Restasis, yes, it is a very complex product. We are advancing our NDA, and we are expected to launch at the start of next year in 2025. We are very hopeful on that.
至於Restasis,沒錯,它是一個非常複雜的產品。我們正在推進我們的NDA,預期在2025年初上市。我們對此非常有信心。
Go ahead, Chirag.
Chirag,你請。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yes, and your health care question, Balaji, it is growing really well, and a lot of government product, (inaudible) DOD, as this is the advantage for -- you get some advantage being the biggest being American company and having manufacturing capacity in America. So, we're taking full advantage of that, and this is why you see the growth in healthcare and it would continue to grow.
好的,Balaji,關於你醫療保健的問題,這塊成長得非常好,而且有很多政府相關產品,(聽不清)國防部(DOD);因為作為最大的美國公司之一、並且在美國擁有製造產能,這會帶來一些優勢。所以我們正充分利用這些優勢,這也是你看到醫療保健業務成長的原因,而且它會持續成長。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
And Balaji, can you just repeat your other question?
Balaji,你可以再重複一下你另一個問題嗎?
Balaji Prasad - Analyst
Balaji Prasad - Analyst
So yes, the impact of healthcare on EBITDA - what I'm also trying to figure out is, with the last 12 months revenue, EBITDA already being close to $590 million, with a stronger revenue trajectory, looking that much clearer for us now, what are the upside/downside risks towards the higher end of your EBITDA guidance? And if the healthcare long-term guidance raise? And what's the impact of AvKARE guidance raised on the EBITDA too?
好的,所以,是的,醫療保健對EBITDA的影響——我也想釐清的是,在過去12個月的營收下,EBITDA已經接近5.9億美元;在更強的營收成長軌跡下,現在對我們來說清晰得多,那麼在你們EBITDA指引區間的高端,存在哪些上行/下行風險?以及醫療保健長期指引上調的影響?另外,AvKARE指引上調對EBITDA的影響是什麼?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
So, what happens, AvKARE has been growing along with the rest of the business. So, we're not relying on any specific segment, whether or not this is generic, AvKARE, specialty, biosimilars - we're going to carry the day, so growth continues to be across all our businesses. Point number one.
所以,發生的情況是,AvKARE 一直隨著整體業務一同成長。因此,我們不依賴任何特定的細分領域,不論是學名藥、AvKARE、專科用藥或生物相似藥——我們都能夠持續推進,因此成長仍然是遍及我們所有業務。第一點。
Point number two is the upside to the downside of the businesses will continue to rely on new product launches, right? A robust, new product approvals and launches to kind of carry the day, so we're not always in control of that. So, that depends, as you know, with the regulatory authority, so some years maybe is ahead of plan, some years we may be a little delayed, but all of those will come.
第二點是,這些業務的上行與下行仍將持續仰賴新產品上市,對吧?也就是要靠強勁的新產品核准與上市來支撐表現,因此這並非總是由我們掌控。所以這取決於監管機關,如你所知,有些年度可能會超前計畫,有些年度可能會稍有延遲,但這些最終都會到來。
But the cadence of it, right, is not totally in our control. So that's something we just want to be mindful of number one.
但其節奏(cadence)對吧,並不完全在我們掌控之中。所以這是我們希望大家首先留意的一點。
Number two is IPX203. So as we discussed, the vast majority of the potential launch expenses of IPX203 are kind of built into our existing guidance, right? So that we worked on. We are conservative. If we get approval, then we will have to look at, I think, a kind of incremental top and bottom-line contribution of that revenue. So, the downside is protected, the upside has not been built in. And healthcare, it just continues to grow nicely. So hopefully, that gives you a sense.
第二點是 IPX203。如我們所討論的,IPX203 潛在上市費用的絕大多數,基本上已納入我們現有的財測指引之中,對吧?這是我們已經做過的工作。我們採取保守作法。如果獲得核准,那麼我們將需要評估我認為該收入對營收與獲利(top line 與 bottom line)的增量貢獻。因此,下行已受到保護,上行尚未納入。而醫療保健業務仍持續穩健成長。希望這能讓你有個概念。
And then the final thing I would say is the type of investments we choose to make, right, to kind of drive, so that a lot of it is variable. It's within our control. So, if we think the year plays out of incredibly well, we may choose to make some additional investments; if the year is playing a little tighter than we thought, we may just kind of push back a couple of potential deals.
最後我想說的是,我們選擇進行的投資類型,對吧,用來推動成長,因此其中很多是可變的。這在我們掌控之內。所以,如果我們認為今年的進展非常順利,我們可能會選擇再做一些額外投資;如果今年的情況比我們想的更緊一些,我們可能就會把幾筆潛在交易往後推。
Balaji Prasad - Analyst
Balaji Prasad - Analyst
Got it. Thanks.
了解。謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
But momentum, Balaji, has been strong as you can see the six key products have been approved already. So, we feel very good on that. The momentum is great, and the pipeline is delivering.
但如你所見,Balaji,動能一直很強,六個關鍵產品已經獲得核准。所以我們對此感到非常有信心。動能很棒,產品管線也在交付成果。
Balaji Prasad - Analyst
Balaji Prasad - Analyst
Congratulations. Thank you.
恭喜。謝謝。
Operator
Operator
Chris Schott, JPMorgan.
JPMorgan 的 Chris Schott。
Chris Schott - Analyst
Chris Schott - Analyst
Great. Thanks so much for the questions. Just a couple for me - maybe first on biosimilar Prolia and XGEVA. Just elaborate a little bit more on the opportunity for these two, and maybe just specifically launch timelines in light of the recent Sandoz settlement, and of the two brands, is it either more interesting to you than the other just given obviously different market dynamics between the two of them?
很好。非常感謝讓我提問。我這邊有幾個問題——首先可能是關於 Prolia 和 XGEVA 的生物相似藥。能否再多談一點這兩者的機會,以及在近期 Sandoz 和解的背景下,特別是上市時程?另外,在這兩個品牌之中,是否有哪一個對你們而言更有吸引力,畢竟兩者的市場動態顯然不同?
Second question, Naloxone, between the public market and retail channel - what are you seeing as the bigger opportunity, and does the opioid settlement at all impact how you think about that? And then maybe just, AvKARE, obviously great performance here, but just your latest thoughts on potential to monetize that business and how you're thinking about that. Thank you.
第二個問題,納洛酮(Naloxone)在公共市場與零售通路之間——你們看到哪一邊的機會更大?鴉片類藥物和解是否會影響你們對此的看法?另外,AvKARE 顯然表現很出色,但想請教你們對該業務變現的可能性以及你們目前的思考。謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Good morning, Chris. So, let's start with biosimilars, Prolia and XGEVA. We are equipped to sell in both channel, the Oncor Encore channel as well as PBM. We expect the launch in 2026, maybe a bit early, and we'll see how the filing -- I think one is early, one is going to be a little bit later.
早安,Chris。那我們先從生物相似藥 Prolia 和 XGEVA 開始。我們具備在兩個通路銷售的能力,包括 Oncor Encore 通路以及 PBM。我們預期在 2026 年上市,可能會稍早一些;至於申報進度——我想其中一個較早,另一個會稍晚一點。
And we expect the market penetration to be very good, because we already have established relationship and by then we'll have more established relationship with the community oncologists, oncology groups, as well as at the hospital groups and contracting PBMs relationship overall. So, we expect to generate a good -- peak sales should go well above $100 million for these products.
我們預期市場滲透率會非常好,因為我們已經建立了既有關係,而且到那時我們與社區腫瘤科醫師、腫瘤團體、醫院體系,以及整體的 PBM 合約合作關係都會更成熟。因此,我們預期能帶來良好的——這些產品的峰值銷售額應可遠超過 1 億美元。
On your second question on Naloxone, the retail side is slow. The government is where most of the demand is, state-wise. Retail is probably 10%, 20%. We already have contracts with CVS and Walgreens to supply them, and they already have supplied them, both of them, and government, state of California - biggest state we get; we are working with other major states, obviously, our home state, and we should be getting more business from government, and this this opportunity will become really big and our settlement does not really impact if you do the maths, which Tony can follow-up with you later on as well. (inaudible) prodcuts as we have $10 million capacity.
關於你第二個問題——納洛酮方面,零售端進展較慢。大部分需求來自政府端,按州別來看。零售大概占 10% 到 20%。我們已與 CVS 和 Walgreens 簽約供貨,也已經向他們兩家供應;而政府端方面,加州是我們拿到的最大州,我們也正與其他主要州合作,當然也包括我們的本州;我們應該會從政府端取得更多業務,這個機會將會變得非常大。而我們的和解其實不太影響——如果你做一下計算,Tony 之後也可以再跟你補充。(聽不清)prodcuts 因為我們有 1,000 萬美元的產能。
So, no issue whatsoever, and AvKARE, as we have said it earlier, strategic options are open. The business is performing really well. We're not in a rush to do anything - if we get the right price, we will transact and de-lever massively or pay down the gross debt in a huge amount, which, it's been a great acquisition for us and either way we're fine with AvKARE.
所以完全沒有問題。至於 AvKARE,如我們先前所說,策略選項保持開放。該業務表現非常好。我們不急著做任何事——如果能拿到合適的價格,我們就會進行交易並大幅去槓桿,或大幅償還總負債;這對我們而言是一筆很棒的收購,不管怎樣我們對 AvKARE 都可以。
Chris Schott - Analyst
Chris Schott - Analyst
Okay, great. Thanks so much.
好的,很好。非常感謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Chris.
謝謝你,Chris。
Operator
Operator
Thank you. We have no further questions, so I will hand back over to Chirag.
謝謝。我們沒有其他問題了,接下來我把時間交還給 Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you. So Q1 was an outstanding start to 2024 as the momentum builds across all areas of our diversified business. The recent Naloxone launch is the latest example, and at Amneal, we love what we do. And our teams are fired up - a high momentum across the company and in all over United States, Ireland, all over India, and we just could not be more excited for overall the health and the performance of our company. So thank you, everyone, and have a great day.
謝謝。因此,隨著我們多元化業務的各個領域動能持續累積,第一季為 2024 年帶來了非常出色的開局。近期納洛酮的上市就是最新的例子;在 Amneal,我們熱愛我們所做的事。我們的團隊士氣高昂——公司上下都充滿強勁動能,遍及全美、愛爾蘭、全印度,我們對公司整體的健康狀況與表現感到無比振奮。所以謝謝各位,祝大家有美好的一天。
Operator
Operator
Thank you, Chirag. This concludes today's call. Thank you for joining. You may now disconnect your line.
謝謝你,Chirag。今天的電話會議到此結束。感謝各位參與。您現在可以掛斷電話。